Physician profile
Joseph Armstrong
NPI 1952037178
$10,913.59
in general payments reported to CMS, 2019-2025
69 companies · $3,932 in 2025
The $3,932 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,121 · 2023: $2,989 · 2024: $2,872 · 2025: $3,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,024 · Education: $768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,024.39 |
| Education | $768.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $833.02 | 2022-2025 | Tagrisso, Enhertu, Lynparza |
| Abbvie INC. | $826.77 | 2022-2025 | |
| Celgene Corporation | $546.17 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Janssen Biotech, INC. | $532.51 | 2022-2025 | Erleada, Darzalex, Rybrevant |
| Pfizer INC. | $517.31 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $474.56 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $416.30 | 2023-2025 | Xtandi, Padcev, Xospata |
| E.R. Squibb & Sons, L.L.C. | $399.79 | 2023-2025 | Opdivo, Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $376.08 | 2023-2025 | |
| Daiichi Sankyo INC. | $374.42 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Seagen INC. | $374.07 | 2022-2025 | Tukysa, Adcetris |
| Incyte Corporation | $370.73 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Lilly USA, LLC | $360.00 | 2022-2025 | Jaypirca, Retevmo, Verzenio |
| Beone Medicines USA, INC. | $337.35 | 2025 | Brukinsa, Tevimbra |
| Bayer Healthcare Pharmaceuticals INC. | $235.32 | 2023-2025 |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $228.15 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $219.75 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.19 | 2023-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Exelixis INC. | $199.94 | 2022-2025 | |
| Array Biopharma INC | $177.66 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Ipsen Biopharmaceuticals, INC | $173.86 | 2023-2024 | Onivyde, Somatuline Depot, Tazverik |
| Mirati Therapeutics, INC. | $171.61 | 2023 | Krazati |
| Eisai INC. | $169.13 | 2023-2025 | |
| Glaxosmithkline, LLC. | $168.17 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Genentech USA, INC. | $146.50 | 2023-2025 | Polivy, Lunsumio, Columvi |
| Amgen INC. | $133.45 | 2023 | Lumakras, Kyprolis, Riabni |
| Karyopharm Therapeutics INC. | $128.65 | 2024-2025 | Xpovio |
| Adc Therapeutics America, INC. | $106.61 | 2024-2025 | |
| Sobi, INC | $103.75 | 2024-2025 | |
| Pharmaessentia USA Corporation | $100.48 | 2023-2025 | Besremi |
| Pharmacyclics LLC, An Abbvie Company | $95.26 | 2023 | Imbruvica |
| Pharmacosmos Therapeutics INC. | $94.64 | 2023-2025 | Monoferric, Cosela |
| Servier Pharmaceuticals LLC | $93.57 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $90.07 | 2023-2025 | Alymsys, Neupogen, Avastin |
| Emd Serono, INC. | $73.32 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.62 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $61.60 | 2022-2024 | Sylvant |
| Accord Healthcare, INC. | $59.29 | 2023-2024 | |
| Menarini Silicon Biosystems, INC. | $51.20 | 2025 | |
| Tolmar, INC. | $49.25 | 2023-2025 | Rubraca |
| Azurity Pharmaceuticals, INC. | $49.21 | 2025 | Danziten |
| Tersera Therapeutics LLC | $47.44 | 2023-2024 | Zoladex |
| Eusa Pharma (US) LLC | $43.76 | 2022 | |
| Stemline Therapeutics INC. | $42.55 | 2023-2025 | Orserdu |
| Foundation Medicine, INC. | $40.54 | 2023 | |
| Agios Pharmaceuticals, INC. | $39.95 | 2023-2024 | Pyrukynd |
| Caris Mpi, INC. | $36.76 | 2025 | Mi Cancer Seek |
| Alexion Pharmaceuticals, INC. | $32.30 | 2023-2024 | Ultomiris |
| Legend Biotech USA INC. | $28.37 | 2025 | Carvykti |
| Kyowa Kirin, INC. | $27.01 | 2025 | |
| Novocure INC. | $25.96 | 2024 | Optune Lua (Novottf-200t) |
| Spectrum Pharmaceuticals INC. | $25.71 | 2025 | Rolvedon |
| Coherus Oncology, INC. | $25.43 | 2025 | Loqtorzi |
| Octapharma USA, INC. | $23.76 | 2023 | Panzyga |
| Mylan Institutional INC. | $23.13 | 2023 | Hulio |
| Aveo Pharmaceuticals, INC. | $22.53 | 2025 | |
| Iovance Biotherapeutics, INC. | $21.44 | 2025 | Amtagvi |
| Geron Corporation | $20.65 | 2025 | Rytelo |
| Pharmaand Gmbh | $20.62 | 2025 | Rubraca |
| G1 Therapeutics, INC. | $19.61 | 2023 | Cosela |
| Cumberland Pharmaceuticals, INC. | $19.33 | 2024 | Sancuso |
| Sun Pharmaceutical Industries INC. | $19.33 | 2025 | |
| Puma Biotechnology, INC. | $19.24 | 2025 | |
| Blue Earth Diagnostics | $18.36 | 2024 | |
| Fennec Pharmaceuticals, INC. | $18.28 | 2025 | Fyarro |
| Regeneron Healthcare Solutions, INC. | $17.79 | 2023 | Libtayo |
| Taiho Oncology, INC. | $17.42 | 2022 | |
| Cti Biopharma Corp. | $13.97 | 2023 | Vonjo |
| Acrotech Biopharma INC. | $12.02 | 2022 |
Drugs and devices associated with these payments
Venclexta $494Reblozyl $469Keytruda $459Xtandi $397Enhertu $319Erleada $287Tagrisso $274Brukinsa $257Opdivo $250Zepzelca $220Tukysa $204Kisqali $203Imbruvica $198Jakafi $186Jaypirca $185Lynparza $180Xofigo $178Nubeqa $178Braftovi $178Krazati $172Lenvima $169Mektovi $156Adcetris $154Retevmo $154Onivyde $153Sarclisa $143Bosulif $136Xpovio $129Orgovyx $125Elahere $124Elrexfio $124Zejula $122Ibrance $119Lorbrena $118Vonjo $118Verzenio $115Talzenna $109Jemperli $106Lumakras $104Darzalex $101Besremi $100Rybrevant $94.69Somatuline Depot $93.62Talvey $88.22Akeega $81.68Balversa $81.68Tevimbra $80.67Datroway $80.61Epkinly $80.30Promacta $77.12Padcev $75.15Alunbrig $73.93Monoferric $72.85Welireg $69.58Monjuvi $67.56Tecvayli $67.36Comirnaty $66.17Paxlovid $66.17Kyprolis $65.75Fruzaqla $63.61Lutathera $62.60Camcevi $59.29Polivy $58.98Vitrakvi $57.55Stivarga $57.55Piqray $55.23Alymsys $52.52Cellsearch $51.20Danziten $49.21Tibsovo $47.81Zoladex $47.44Opdualag $45.20Zynyz $44.26Columvi $42.81Lunsumio $42.81Cablivi $42.64Enjaymo $42.64Orserdu $42.55Xalkori $42.50Sylvant $41.73Cosela $41.40Rubraca $39.96Pluvicto $38.10Riabni $37.09Mi Cancer Seek $36.76Xgeva $35.88Tecentriq $34.71Ojjaara $33.05Injectafer $32.33Ultomiris $32.30Eligard $29.91Carvykti $28.37Poteligeo $27.01Zynlonta $26.48Optune Lua (Novottf-200t) $25.96Ninlaro $25.80Rolvedon $25.71Loqtorzi $25.43Iclusig $24.97Idhifa $23.83
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.